Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab

Journal of Neuro-Oncology

Volumn 104, Issue 2, 2011, Pages 595-598

  Vargo, J A ^a   Snelling, B M ^a   Ghareeb, E R ^a   John, K ^b   Frame, J N ^b,c   Schmidt, J H ^b   Peters, K B ^d  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b West Virginia University School of Medicine Charleston   (United States)

^c CHARLESTON AREA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaplastic astrocytoma; Bevacizumab; Dural sinus vein thrombosis; Venous thromboembolism

Indexed keywords

BEVACIZUMAB; COLONY STIMULATING FACTOR; DEXAMETHASONE; ENOXAPARIN; GADOLINIUM; HEPARIN; STEROID; TEMOZOLOMIDE;

ADULT; ARTICLE; BRAIN BIOPSY; BRAIN EDEMA; BRAIN RADIATION; CANCER GRADING; CASE REPORT; CEREBRAL SINUS THROMBOSIS; CONTRAST ENHANCEMENT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; HUMAN TISSUE; LABORATORY TEST; MIGRAINE AURA; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOGRAPHY; RADIATION DOSE; TUMOR DIFFERENTIATION; VERTIGO; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DURA MATER; FEMALE; HUMANS; RADIOTHERAPY; SINUS THROMBOSIS, INTRACRANIAL;

EID: 80052631833     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0519-8     Document Type: Article

References (20)

1. MH Cohen YL Shen P Keegan R Pazdur 2009 FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme The Oncologist 14 1131 1138 19897538 10.1634/theoncologist.2009-0121 1:CAS:528:DC%2BC3cXjt1eqsw%3D%3D
2. F Elice J Jacoub FR Rickles A Falanga F Rodeghiero 2008 Hemostatic complications of angiogenesis inhibitors in cancer patients Am J Hematol 83 862 870 18819092 10.1002/ajh.21277 1:CAS:528:DC%2BD1cXhsVyntLnI
3. MS Gordon D Cunningham 2005 Managing patients treated with bevacizumab combination therapy Oncology 69 25 33 16301833 10.1159/000088481 1:CAS:528:DC%2BD2MXht1aqsrbP (Pubitemid 41680950)
4. AA Khorana MV Rao 2007 Approaches to risk-stratifying cancer patients for venous thromboembolism Thromb Res 120 S41 S50 18023712 10.1016/S0049-3848(07) 70129-9 (Pubitemid 350103848)
5. A Lai E Filka B McGibbon PL Nghiemphu C Graham WH Yong P Mischel LM Liau M Bergsneider W Pope M Selch T Cloughesy 2008 Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability Int J Radiat Oncol Biol Phys 71 1372 1380 18355978 10.1016/j.ijrobp.2007.11.068 1:CAS:528:DC%2BD1cXoslWqsLo%3D
6. Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Herndon JE, Kirkpatrick J, Gururangan S, Baily L, Friedman AH, Friedman HS (2009) Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 27S:2015. ASCO Annual meeting proceedings
7. A Desjardins DA Reardon JE Herndon J Marcello JA Quinn JN Rich S Sathornsumetee S Gururangan J Sampson L Bailey DD Bigner AH Friedman HS Friedman JJ Vrendenburgh 2008 Bevacizumab plus irinotecan in recurrent WHO grade III malignant gliomas Clin Cancer Res 14 7068 7073 18981004 10.1158/1078-0432.CCR- 08-0260 1:CAS:528:DC%2BD1cXhtlens7fJ
8. TN Kreisl L Kim K Moore P Duic C Royce I Stroud N Garren M Mackey JA Butman K Camphausen J Park PS Albert HA Fine 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 740 745 19114704 10.1200/JCO.2008.16.3055 1:CAS:528:DC%2BD1MXjsVCjs7o%3D
9. JJ Vredenburgh A Desjardins JE Herndon J Marcello DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan J Sampson M Wagner L Bailey BD Darell AH Friedman HS Friedman 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722 4749 17947719 10.1200/JCO.2007.12.2440 1:CAS:528:DC%2BD2sXhtlCgsLjF (Pubitemid 350086473)
10. JJ Vrendenburgh A Desjardins JE Herndon JM Dowell DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan M Wagner DD Bigner AH Friedman HS Friedman 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 1253 1259 10.1158/1078-0432.CCR-06-2309 (Pubitemid 46424067)
11. HS Friedman MD Prados PY Wen T Mikkelsen D Schiff LE Abrey WK Yung N Paleologos MK Nicholas R Jensen J Vredenburgh J Huang M Zheng T Cloughesy 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 4733 4740 19720927 10.1200/JCO.2008.19.8721 1:CAS:528: DC%2BD1MXhtlGgtbbM
12. Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Kirkpatrick J, Herndon JE, Marcello J, Bailey L, Threatt S, Friedman HS (2010) Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). J ClinOncol 28S:2023. ASCO Annual meeting proceedings
13. Health canada endorsed important safety Information on Avastin (bevacizumab). Available from http://www.hc-sc.gc.gc.ca/dhp-mps/alt-formats/ hpfb-dgpsa/pdf/medeff/avastin-pc-cp-eng.pdf. Accessed 10 July 2010
14. Avastin (bevacizumab) Prescribing Information. Available from http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf. Accessed 10 July 2010
15. SR Nalluri D Chu R Keresztes X Zhu S Wu 2008 Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2277 2285 19017914 10.1001/jama.2008.656 1:CAS:528:DC%2BD1cXhtlyrt77O
16. E Pan JS Tsai SB Mitchell 2009 Retrospective study of venous thromboembolic and intracereberal hemorrhagic events in glioblastoma patients Anticancer Res 10 4309 4313
17. A Ozen I Cicin A Sezer S Uzunoglu M Saynak H Genchellac H Karagol 2009 Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab J Can Res Ther 5 130 132 10.4103/0973-1482.52791
18. JM Ferro P Canhão J Stam MG Bousser F Barinagarrementeria ISCVT Investigators 2004 Prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and dural sinus thrombosis Stroke 35 664 670 14976332 10.1161/01.STR.0000117571.76197.26 (Pubitemid 38280838)
19. A Filippidis E Kapsalaki G Patramani KN Fountas 2009 Cerebral venous sinus thrombosis: review of the demographics, pathophysiology, current diagnosis, and treatment Neurosurg Focus 27 E3 19877794 10.3171/2009.8. FOCUS09167
20. JJ Razier LM DeAngelis 2000 Cerebral sinus thrombosis diagnosed by MRI and MR venography in cancer patients Neurology 54 1222 1226